Related Experiment Videos
Somatostatin: an alternative to sclerotherapy?
1Dept. of Surgery, Glasgow Royal Infirmary, UK.
Scandinavian Journal of Gastroenterology. Supplement
|January 1, 1994
Summary
Somatostatin effectively controls acute esophageal variceal bleeding and prevents early rebleeding. This safe treatment offers a vital option for managing this serious medical emergency.
Area of Science:
- Gastroenterology
- Hepatology
- Emergency Medicine
Background:
- Esophageal variceal bleeding is a life-threatening emergency with high mortality (30-40%).
- Active bleeding occurs in 30-40% of patients, necessitating urgent intervention to prevent hypovolemic shock.
Purpose of the Study:
- To evaluate somatostatin as a safe and effective treatment for acute variceal hemorrhage.
- To assess somatostatin's efficacy in preventing early rebleeding.
Main Methods:
- A randomized controlled trial compared somatostatin to injection therapy.
- Efficacy was assessed for acute bleeding control and recurrent bleeding within 5 days.
Main Results:
- Somatostatin demonstrated comparable efficacy to injection therapy in controlling acute variceal bleeding.
- Somatostatin was effective in reducing the incidence of early rebleeding.
Conclusions:
- Somatostatin is a safe and effective therapeutic option for acute variceal hemorrhage.
- Somatostatin successfully prevents early rebleeding in patients with esophageal varices.